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Abstract
Antiphospholipid syndrome (APS) is an autoimmune disease, characterized by
thrombosis and pregnancy complications with persistently elevated levels of
antiphospholipid antibodies (aPL). Recently, a unique mathematical calculation has
been presented to assess the risk of thrombosis in patients with APS called antiphos‐
pholipid score or global antiphospholipid syndrome score (GAPSS). This new
approach in the diagnosis of APS leads to the assessment of the risk of thrombosis
considering the results of different aPL (lupus anticoagulants (LA), anticardiolipin
antibodies (aCL), antibodies against β2GPI (anti-β2GPI), and phosphatidylserine-
dependent antiprothrombin antibodies (aPS/PT) (isotypes IgG and IgM). This chapter
provides an overview of the algorithm strategy for APS diagnosis with the aims of
characterizing in detail the laboratory methodology of criteria aPL (LA, aCL, and anti-
β2GPI) and noncriteria aPL, such as IgA aCL and IgA anti-β2GPI, anti-domain I
β2GPI, and antiprothrombin antibodies. In order to improve APS diagnosis, several
new approaches in aPL detection have recently been suggested, such as multiline
immunodot assay, detection of aPL by flow cytometry using beads with particular
surface properties, and the newly developed automated BioPlex system technology
for parallel detection of aCL and anti-β2GPI antibodies of IgG, IgA, and IgM isotypes.
A completely different and promising approach in future research lies in the potential
of microRNAs as biomarkers for risk of thrombosis and/or obstetric complication.
Keywords: Anticardiolipin antibodies, lupus anticoagulants, anti-beta2-glycoprotein I an‐
tibodies, antiprothrombin antibodies, ELISA, multiplex assays, microRNA studies
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1. Introduction
The antiphospholipid syndrome (APS) or Hughes syndrome was first described three decades
ago in patients with systemic lupus erythematosus and positive pathogenic autoantibodies
named antiphospholipid antibodies (aPL), who experienced arterial or venous thrombosis [1].
APS is now recognized as an autoimmune disease, characterized by thrombosis and pregnancy
complications with persistently elevated levels of aPL. While deep veins of the lower limbs
and the cerebral arterial circulation are the most common sites of venous and arterial throm‐
bosis, any tissue or organ can be affected [2]. The risk of recurrent thrombosis in APS over 5
years is 16.6% despite the use of anticoagulants and/or salicylates [3, 4]. APS is also associated
with a 5-year mortality of 5.3% with most deaths occurring within the first year of diagnosis
due prevalently to bacterial infections, myocardial infarction, stroke, and cerebral hemorrhage
[5]. The catastrophic APS (CAPS) is a rare life-threatening form of APS in which widespread
intravascular thrombosis results in multiorgan ischemia and failure. Intravascular thrombosis
affecting predominantly microcirculation characterizes CAPS. In addition, thrombosis of
arteries, veins, or both can occur. CAPS affects about 1% of cases with APS and is the initial
presentation of APS in nearly half of patients, while the remaining half has a history of APS
[6–9]. Despite aggressive treatment, mortality rates still range between 44.0% and 55.6% [5,
10]. The other major clinical manifestations of APS are obstetrical. They include the unex‐
plained death of one or more morphologically normal fetuses at or beyond the 10th week of
gestation, the premature birth of one or more morphologically normal neonates before the 34th
week of gestation due to eclampsia, severe preeclampsia, or recognized features of placental
insufficiency, and three or more unexplained consecutive spontaneous abortions before the
10th week of gestation.
According to the international consensus statement on classification criteria established in 1999
in Sapporo and updated in 2006 in Sydney, APS is classified when persistently elevated levels
of specific aPL are confirmed in addition to clinical manifestations [11, 12]. These consensus
classification criteria for definite APS enabled substantial improvement in APS recognition
(Figure 1); however, the diagnosis of APS still remains difficult. In the general population, the
incidence of clinical manifestations which can be included in APS is high and could often be
triggered by other underlying factors. Consequently, the diagnosis of APS relies predomi‐
nantly on the laboratory results. The laboratory criteria comprise persistently elevated levels
of either lupus anticoagulant (LA) or IgG/IgM antibodies to cardiolipin (aCL) or antibodies to
β2GPI (anti-β2GPI). Methods for their determination differ and have not yet been standardized
[13]. The common weaknesses of aPL determination are high interassay and interlaboratory
variations, problems with the interpretation and clinical evaluation of the test results, as well
as their low diagnostic specificity. Elevated aPL can be associated with many other conditions
such as infections, malignancy, and also exposure to certain drugs. The absence of reliable,
robust diagnostic markers for APS thus limits patient identification and management which
challenges researchers to find better diagnostic marker(s). Among many autoantibodies that
have been found to be associated with APS but not included in the current laboratory criteria,
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antiprothrombin antibodies have shown the highest diagnostic applicability. Moreover,
antiprothrombin antibodies are often present in APS patients and are sometimes the only aPL
elevated [14, 15]. A recently published review concluded that an immunoassay using phos‐
phatidylserine/prothrombin (aPS/PT ELISA) as an antigen on solid phase, leads to higher
diagnostic accuracy as compared to the method using prothrombin alone (aPT ELISA) [14]. It
seems that in the future there might be a change in the perception of the role of aPL from the
criterion for APS classification to the role of risk factors estimating the probability for devel‐
oping APS clinical manifestation. Modern trends for the diagnostic evaluation of APS patients
therefore propose a determination of multiple classes of aPL, among them also antiprothrom‐
bin antibodies, to gain a common score which estimates the risk for arterial/venous thrombosis
in APS patients [16–18]. Risk stratification is a major challenge in treating patients with APS
and a potential role of aPL as a risk or even as a prognostic factor for arterial/venous thrombosis
and miscarriages has been intensively debated [16, 19]. Single, double, and triple aPL positivity
is not rare in patients with APS and such multiple positivity is mostly associated with higher
risk for appearance or recurrence of thrombotic events and miscarriages [20, 21]. Recently, two
research groups presented a unique mathematical calculation to assess the risk of thrombosis
in patients with APS (called antiphospholipid score or global antiphospholipid syndrome
score-GAPSS) [16, 17]. This new approach in the diagnosis of APS leads to the assessment of
the risk of thrombosis considering the results of different aPL (LA, aCL, anti-β2GPI, and
aPS/PT—isotypes IgG and IgM). The common calculation can help clinicians decide about
introducing, eliminating or changing the appropriate therapy.
In order to improve APS diagnosis, several new approaches in aPL detection have recently
been suggested. One is to detect aPL antibodies by multiline immunodot assay which may
provide an interesting alternative to ELISA. Multiline immunodot assay could be a candidate
for an effective multiparameter test system and simultaneous, semi-quantitative detection of
several aPL antibodies in one sample; however, the technique has not yet been widely studied
[22]. Apart from the immunodot technique, the detection of aPL by flow cytometry using beads
with particular surface properties could represent another promising approach in aPL
antibody multiplex testing [23]. Very recently, an automated technology for the parallel
detection of aCL and anti-β2GPI antibodies of IgG, IgA, and IgM isotypes was developed in
the BioPlex system [24]. The instrument combines the multianalyte profiling technology with
antigen-coated fluoromagnetic beads in an automated platform where sampling, processing,
and data reduction are performed automatically.
A completely different and promising approach in future research lies in the potential added
value of microRNAs (miRNAs) as biomarkers for risk of thrombosis and/or obstetric compli‐
cation. These are small noncoding RNAs that regulate gene expression at the posttranscrip‐
tional level by degrading or blocking translation of messenger RNAs. Many miRNAs have
been found significantly altered in sera or plasma of patients with thrombosis [25] or specific
pregnancy complications [26, 27].
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*Anti-annexin V antibodies, anti-phosphatidylethanolamine, antibodies to domains of β2GPI, antibodies against anion‐
ic phospholipids other than cardiolipin [28, 29].
Figure 1. Algorithm strategy for APS diagnosis. APS: antiphospholipid syndrome; aCL: anticardiolipin antibodies, an‐
ti-β2GPI: antibodies against β2 glycoprotein I; aPS/PT: antiphosphatidylserine prothrombin antibodies; aPL: antiphos‐
pholipid antibodies, LA: lupus anticoagulant.
2. Criteria aPL
Despite several attempts to standardize the LA, aCL, and anti-β2GPI tests, a considerabledegree of interlaboratory variation still exists [13, 30]. While many laboratories worldwide
Thrombosis, Atherosclerosis and Atherothrombosis - New Insights and Experimental Protocols108
have managed to obtain consistently reproducible LA, aCL, and anti-β2GPI results, there are
others that still report variations between different runs, which may potentially affect the
consistency of the diagnosis of APS. This is mainly due to laboratories performing in-house
aPL assays or using commercial kits not conforming to proposed guidelines for these tests [11].
Such apparent inconsistencies limit clinical usefulness and effectiveness as well as interlabor‐
atory comparability of LA, aCL, and anti-β2GPI tests results. In general, aPL assays are very
heterogeneous, poorly standardized, poorly harmonized, and consequently diversely sensi‐
tive and specific for APS. The standardization of autoantibodies assay is still a challenging
task, and particularly limited progress has been made in the detection of aPL. Therefore,
comparison studies are needed to further analyze the agreement between the different
technologies.
It is well known that different assays for the detection of aPL show different sensitivities. By
one plausible speculation LA assay is relatively “undersensitive” to aPL, so that only higher
titre and more clinically relevant forms of aPL are detected by the clot-based tests [31]. On the
other hand, immunoassays, such as aCL, may be “oversensitive,” as they detect both clinically
relevant and clinically irrelevant (e.g., infection-associated) forms of aPL. Furthermore, aCL
test more often detect “low levels” of aPL that are less likely associated with APS than LA
assay. The hypothesis is also supported by the observation that a positive result in the anti-
β2GPI assay (which is theoretically more “specific” but less “sensitive” than aCL for APS), is
more strongly associated with clinical features of APS such as thrombosis than a positive result
in the standard aCL assay [30]. For the physician, it is important to have in mind there is no
gold standard aPL assay when defining the presence or absence of APS. However, data are
emerging that the combination of multiple aPL findings is a superior risk stratification tool for
clinical events in APS such as thrombosis [32, 33]. According to the revised classification
criteria, APS patients should be divided into four categories: category I includes patients with
more than one positive test in any combination, while patients with a single positive test should
be classified in category II (IIa if LA positive, IIb if positive for antibodies against CL (aCLs),
and IIc if positive for anti-β2GPI antibodies) [11]. Triple positivity, defined by the presence of
LA and medium/high titers of aCL and anti-β2GPI antibodies (above the 99th percentile), is
the most predictive profile for clinical manifestations and recurrences despite conventional
treatment [34–36]. Patients in category II, expressing single aPL positivity, have a lesser risk
to develop APS manifestations.
2.1. Lupus Anticoagulants (LA)
LA denotes a subgroup of aPL antibodies that prolong phospholipid-dependant clotting
reactions. The clotting-based nature of the LA assay is fraught with preanalytical limitations,
the need for multiple reagents, diversity in platforms, as well as challenges with interpreting
results. It was shown that the presence of LA correlates better with thromboembolic compli‐
cations than the presence of aCL [4]. The superiority of LA over aCL was explained by the
nature of the assay; LA measures the activity of aPL, while in an ELISA, both the antibodies
that influence functional activity and the antibodies that have no aPL activity are measured
[37]. However, LA testing has several drawbacks, such as the absence of a reference method,
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low degree of standardization, and difficult test result interpretation. Consensus guidelines
for the detection of LA were first published in the 1990s [38, 39]. Significant improvement in
standardization has been achieved with the updated guidelines of the Scientific Standardiza‐
tion Subcommittee (SSC) of the International Society Thrombosis and Haemostasis in 2009 [40]
and with the Clinical and Laboratory Standards Institute (CLSI) document in 2014 [41] that
has resolved several issues of the preanalytical, analytical, and post-analytical phase.
The preanalytical phase plasma preparation is the crucial step. Plasma for LA analysis must
be rendered platelet poor (platelet count less than 10 × 109/L), as residual platelets contain
phospholipids that can shorten clotting times and generate false-negative results. Double
centrifugation of blood is preferred, although a single centrifugation can also be suitable if the
recommended platelet count is achieved. Ultracentrifugation as the second step is discouraged
due to possible generation of phospholipid-containing microparticles [42]. Filtration through
0.22 µm cellulose acetate filters is also discouraged because of the binding of coagulation
factors V, VIII, IX, XII, and von Willebrand factor to the filter [43]. Whether assays, such as
dilute Russell’s viper venom time (dRVVT), that bypass these coagulation factors are affected
by filtration has not yet been studied.
Testing may be performed on fresh or properly frozen/thawed samples [41]. According to our
experience, however, all the samples should be treated in the same manner as were plasma
samples of healthy donors from which the reference values were obtained. For example, we
found significantly longer activated partial thromboplastin times (APTTs) measured with the
Staclot LA (Diagnostica Stago, France) on Behring Coagulation Timer (Dade Behring, Germa‐
ny) in fresh (73.0 ± 17.7 s screening and 59.6 ± 12.1 s confirming test) compared to frozen/thawed
plasma (59.8 ± 9.3 s screening and 53.7 ± 4.2 s confirming test, both paired t-test p < 0.05), while
no differences were found for the dRVVT assay.
Several plasma-based (clotting) assays were traditionally used for LA detection that include
intrinsic, extrinsic, or common coagulation pathway. On one hand, no single assay is 100%
sensitive and specific for LA; therefore, the use of more than one assay was recommended. On
the other hand, by increasing the number of different assays, the probability of false-positive
results increases [44]. Guidelines therefore suggest using (no more than) two assays that are
known to be responsive to LA, preferably dRVVT and APTT [41, 44].
Several strategies that include screening and confirming tests (with or without the mixing test)
can be used for LA detection (Figure 2). In the screening test, low phospholipid levels are used,
while confirmation test, preferably based on the same principle as the screening test, utilizes
high phospholipid levels.
Each laboratory should establish its own cutoff value for a screening test above which confirm‐
ing (and mixing) test needs to be performed. The SSC guidelines recommend using the 99th
percentile [44], while the CLSI guidelines recommend average + 2 standard deviations (equal
to 97.5th percentile) as the appropriate cutoff [41]. It should be noted that a higher cutoff insures
less false-positive results, but a false-positive screening test from a statistical outlier in case of
the lower cutoff will not generate false-positive composite interpretation. Yet a false-negative
result in case of the higher cutoff could lead to inappropriate diagnosis and treatment [42].
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The need for a mixing test has been highly debated. When using an integrated test system
(Figure 1, right panel), a mixing step is not necessary, and many laboratories avoid this step
because of the additional work, cost, testing time, and the need for normal pool plasma. In
addition, it is not clear how the mixing test should be performed (patient to normal pool plasma
volume ratio, incubation time). Finally, there is some evidence that the mixing step produces
false-negative results where a weak but clinically relevant LA is present [45]. On the other
hand, integrated test systems without the mixing step may produce false-positive [46] as well
as false-negative results [34]; therefore, further studies are needed.
LA testing results should be expressed as the normalized screen to confirm ratio [41, 44] as this
practice reduces the variability of the analyzer and reagent performance. When the result is
positive, additional assays, such as prothrombin time (to exclude vitamin K antagonists),
thrombin time (to exclude heparin or direct thrombin inhibitor), and anti-Xa (to exclude low-
molecular-weight heparin or direct factor Xa inhibitor), may be performed to make sure that
the patient is not on anticoagulant therapy. The test panel should be repeated at or beyond 12
weeks to determine persistence of the LA [41, 44]. Laboratories should provide the final
interpretation of LA testing results as positive (LA present), negative (LA not detected), or
inconclusive (to be retested).
LA testing remains much more labor intensive and complicated to perform than ELISA but
must be performed in parallel with aCL and anti-β2GPI. Significant improvement has been
achieved through SSC guidelines [44], but some issues are still unresolved and further reports
of the SSC are awaited.
2.2. Anticardiolipin antibodies
The first molecularly defined aCL test was a radioimmunoassay established in 1983, using
cardiolipin as an antigen, with a mixture of gelatin/PBS to dilute patient serum and radiola‐
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Figure 2. Strategies for LA detection. LA: lupus anticoagulant.
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beled anti-human IgG or IgM secondary antibodies. In 1990, three groups independently
reported that aCL do not bind to cardiolipin in the absence of serum proteins, as summarized
by Roubey [47]. The designation is somewhat misleading because aCL are an undefined group
of antibodies that bind directly (1) to the cardiolipin (CL) and (2) to various (usually calf or
bovine) serum proteins (most likely β2GPI) linked to CL. The first group are β2GPI-independent
aCL (binding to CL does not require this cofactor), which are often associated with infectious
diseases. Infectious aCL do not pose a risk for the occurrence of clinical signs associated with
APS and are therefore indicated as nonthrombogenic autoantibodies. Infectious diseases can
therefore determine the transient aCL positivity. Patients with syphilis, HIV, Lyme disease,
and other infections triggered by cytomegalovirus, hepatitis C, and Epstein–Barr viruses may
be mistakenly diagnosed as APS based on high levels of aCL especially, when concomitant
arterial thrombosis or cerebrovascular accident is present [48]. In the second group, antibodies
against β2GPI prevail. These are the β2GPI-dependent aCL antibodies (aCL/β2GPI), which
require the presence of cofactor β2GPI for their binding to CL. They are characteristic of
autoimmune diseases, as high titers of these antibodies detected in plasma represent a risk for
thromboembolic complications. Therefore, for the detection of aCL (IgG and IgM), an ELISA
method is used [49, 50], which measures the immune reactivity to CL as a phospholipid or to
β2GPI as a protein bound to phospholipids. The affinity of β2GPI for CL is 30 to 40 times higher
than affinity to phosphatidylserine [51]. Briefly, the ELISA test involves medium binding
microtitre plates coated with highly purified negatively charged CL incubated overnight at
4°C and diluted patients sample in bovine serum (FBS), which acts as a cofactor for the
recognition of CL as the antigen. After 2.5 h incubation at room temperature and two washes,
goat antihuman IgG or IgM conjugated with alkaline phosphatase diluted in FBS/PBS was
applied to the plates. Following washing, para-nitrophenylphosphate in diethanolamine
buffer (pH 9.8) was applied, and optical density at 405 nm (OD405) was kinetically measured
by a spectrometer (Figure 3) [50, 52]. The essential weakness of this assay is that patients with
aCL antibodies that bind human but not bovine β2GPI can be missed. Therefore, some
laboratories use human β2GPI instead of bovine or calf serum as a source of β2GPI in the aCL
ELISA.
Several international workshops and forums have been conducted in an attempt to standardize
the aCL test [53–58]. Despite these efforts, a considerable degree of interlaboratory variation
still exists [59]. There is also a high degree of variability between different commercial kits for
the detection of aCL even when assessed within the same laboratory, with lower variability
seen with different commercial anti-β2GPI kits [60]. This keeps raising the question of the
standardization of commercial and/or in-house laboratory methods and results [61]. Although
laboratory results represent an essential contribution to the diagnosis of APS, many questions
regarding methodology and reference values of various in-house and commercially available
kits that are not comparable still remain unanswered. In an effort to improve the diagnostic
value of aPL antibody assays, aCL determination is still necessary and should be comple‐
mented by anti-β2GPI determination in accordance with revised Sydney laboratory classifica‐
tion criteria for the diagnosis of APS [11].
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Figure 3. Laboratory protocols for aCL, anti-β2GPI, and aPS/PT ELISA. BSA: bovine serum albumin; conjugate: goat
antihuman IgG/M/A conjugated with alkaline phosphatase; DEA: diethanolamine buffer; FBS: fetal bovine serum; PBS:
phosphate-buffered saline; pNPP: para-nitrophenylphosphate; RT: room temperature; TBS: tris buffer saline; Tw20:
Tween-20.
2.3. Antibodies against β2GPI
A large part of autoantibodies in patients with APS are directed against β2GPI and anti-β2GPI
therefore represent one of the main subgroups of antiphospholipid antibodies [62]. β2GPI, also
known as apolipoprotein H, is a multifunctional and evolutionary conserved single-chain
glycosylated protein present in plasma at concentrations ~180 mg/L (range 20–300 mg/L) [63–
65]. The major site of β2GPI synthesis is the liver, although its mRNA has also been found in
endothelial cells, neurons, astrocytes, and in the extra villous cytotrophoblast and syncytio‐
trophoblast of placenta [66]. The ~50-kDa protein consists of 326 amino acids, which are folded
into five short consensus repeat domains, termed also “sushi” domains. Domains I–IV are
composed of ~ 60 amino acids, and each contains two disulfide bridges, while the domain V
consists of 82 amino acids. Domain V also has specific characteristics, such as a positively
charged, lysine-rich region, a hydrophobic loop, and a 19-residue C-terminal extension, which
is cross-linked by an additional disulfide bond allowing β2GPI to bind to negatively charged
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phospholipids [67–70]. Due to specific interactions between the domains I and V of β2GPI, the
protein exists in three configurations, i.e., circular plasma protein, as observed by electronic
microscopy [71], open fishhook conformation, as revealed by its crystal structure [69, 72], and
an intermediate S-shape, which has been recently observed using small-angle X-ray scattering
[73]. After binding to suitable anionic surface, for example, to phospholipids, β2GPI changes
its conformation from circular to open (“J”), exposing a cryptic epitope, which is recognized
by anti-β2GPI-directed against domain I [74].
Although routine laboratories detect and interpret anti-β2GPI as one set of autoantibodies, they
actually represent a very heterogeneous group directed against the same antigen. Due to their
polyclonal nature subpopulations of anti-β2GPI vary in epitope recognition [63, 75–78], avidity
[79–82], and pathological mechanisms of their action [63, 83, 84], which results in their different
pathogenicity and clinical relevance [63, 77, 78, 80, 85, 86]. A subset of IgG anti-β2GPI directed
against domain I on β2GPI seems to have a prominent role in the pathology of thrombotic
complications in patients with APS [74]. According to de Laat et al. [87], pathologic anti-β2GPI
can be divided into those targeting epitope on domain I (directed against the G40-R43
residues), which highly correlate with thrombosis, and those targeting nondomain I epitopes.
According to Giannakopoulos et al. [88], these differences are due to anti-β2GPI avidity.
Therefore, avidity must also be considered when describing the diversity of anti-β2GPI
subpopulations and their clinical relevance. Several research groups/clinical studies indicated
that difference in strength of binding to the same antigen/same epitope could be an important
marker of the pathogenicity of the specific anti-β2GPI subgroups [80, 85, 89]. An association
between high-avidity IgG anti-β2GPI and thrombotic or obstetric complications in patients
with APS was reported [85, 90]. This was in contrast to low-avidity IgG anti-β2GPI, which was
more prevalent in autoimmune patients without APS. The involvement of high avidity IgG
anti-β2GPI in the pathogenesis of APS was also confirmed in an in vitro study on human
coronary artery endothelial cells [91]. In this study, high-avidity IgG anti-β2GPI was shown to
increase the expression of inflammatory and chemotactic cytokines leading to higher migration
of monocytes. These effects were further intensified in presence of the major acute phase
protein serum amyloid A (SAA) [91], denoting that along with lipopolysaccharide [83], SAA
as a marker of inflammation, also represents a trigger or a second hit uncovering the full
pathological potential of anti-β2GPI [91]. The differences among antigen binding sites on anti-
β2GPI of differently avidity were further confirmed by the location of the recognized epitopes
on β2GPI. Therefore, using heptamer phage display libraries two binding epitopes of high-
avidity IgG anti-β2GPI have been characterized: FNPYWYV and QGOAHSK [92]. These
sequences mimicked specific amino acid clusters on domains II and III of β2GPI and were
accessible to high-avidity IgG anti-β2GPI in the fishhook and circular conformations. In
contrast, the sequence KMDGNHP has been characterized as a surface binding epitope for
low-avidity IgG anti-β2GPI located between domains III and IV of β2GPI. It was accessible for
the binding of low-avidity IgG anti-β2GPI only in the open/fishhook conformation [92].
Epitopes of low-avidity IgG anti-β2GPI are cryptic and not reachable for the antibodies when
β2GPI molecules occupy the closed plasma conformation, which explains a negligible binding
of the respective anti-β2GPI to β2GPI in the solution. Epitopes of high-avidity IgG anti-β2GPI
are native and reachable regardless of conformation of the β2GPI, which is in accordance with
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the proven binding of the respective anti-β2GPI to antigen in the solution. High-avidity
monoclonal anti-β2GPI recognizes β2GPI in the solution by binding to the epitope, which is
crucial for the restoration of the closed conformation of the β2GPI [81]. Since enzyme-linked
immunosorbent assays currently used in routine diagnostics detect anti-β2GPI antibodies of
unknown avidity, these observations are potentially useful for the development of improved
diagnostic tests capable of detecting clinically relevant antibodies. The avidity of IgG anti-
β2GPI was determined by chaotropic anti-β2GPI ELISA [79]. The procedure was in principle
the same as in the anti-β2GPI ELISA, using chaotropic conditions during antibody binding.
Samples were diluted in PBS–Tween containing increasing concentration of NaCl. Discrimi‐
nation between anti-β2GPI with high or low avidity was made arbitrarily, comparing the initial
binding at 0.15 M NaCl with bindings at higher salt concentrations [79, 85]. NaCl (0.5 M) was
selected as the reference concentration for comparison with the initial binding. When the
binding at 0.5 M NaCl remained higher than 70% of the initial one, the presence of high-avidity
anti-β2GPI was declared. When the binding at 0.5 M NaCl decreased to or below 25% of the
initial binding, low-avidity anti-β2GPI were designated. Samples that did not fulfill either of
the above criteria were considered to be of heterogeneous avidity [79].
The addition of anti-β2GPI antibodies to the revised Sydney laboratory classification criteria
for the diagnosis of APS was finalized in 2006 [11]. According to the consensus guidelines on
anti-β2GPI testing and reporting [93], IgG anti-β2GPI should be performed on all requests for
anti-β2GPI where isotype is not specified. If both IgG and IgM anti-β2GPI antibody testing is
routinely performed on all requests (regardless of whether IgM anti-β2GPI testing has been
specifically requested), then it has been suggested that a comment should be provided to the
physician indicating that the association between isolated positive IgM anti-β2GPI results and
thrombosis is uncertain but appears to be lower than for IgG anti-β2GPI [93].
ELISA that measures the immune reactivity directly to β2GPI is used for the detection of anti-
β2GPI (IgG and IgM). The characteristics are similar to the detection of aCL with the major
difference that in anti-β2GPI ELISA, the purified human native β2GPI [94] is coated directly
onto the ELISA microtitre plates. Briefly, high binding polystyrene microtitre plates were
coated with β2GPI in PBS and incubated with sera diluted in PBS containing 0.05% Tween-20.
The detection system was the same as in aCL ELISA (Figure 3). Anti-β2GPI is directed against
a cryptic epitope exposed when β2GPI is bound to anionic phospholipid or another suitable
surface [95]. Namely, some brands of ELISA plates are unable to induce the conformational
change due to difference in structure or charge and are unsuitable for use in anti-β2GPI ELISA
[95]. There remains a lack of a formal, universally accepted method for performing anti-β2GPI
ELISA, coupled with a lack of standardized WHO accepted calibrators. The in-house and
commercial kits are calibrated by their own “calibrators” and expressed in arbitrary units.
Consequently, there is a great variability in the results reported by the different laboratories.
Meroni et al. suggested that the identification of common calibrators may be useful in obtaining
more reproducible results [96]. Both polyclonal IgG/IgM anti-β2GPI antibodies affinity-
purified from two APS patients with high IgG and IgM anti-β2GPI levels and chimeric
monoclonal IgG antibody (INOVA, San Diego, CA, USA) reacting with human β2GPI have
been selected as candidates for reference material for calibration [97]. This reference material
may contribute significantly to better standardization of anti-β2GPI immunoassays.
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3. Noncriteria aPL
The majority of APS patients have APS, as defined by the presence of clinical features and
positive one or more laboratory criteria aPL. However, a small proportion of patients have
significant clinical features of APS but lacking persistently elevated above-mentioned criteria
aPL. These so-called “seronegative” APS patients (SNAPS) probably do exhibit certain aPL,
which may not be identifiable given the limitations of currently available aPL assays. Even if
such a patient does not fully satisfy the classification criteria, he/she may still have APS.
Missing a diagnosis of APS in these individuals may lead to the absence of appropriate therapy
and potentially significant adverse outcomes for such patients. For clinical studies, patients
falling into any of these categories should be classified separately from those that fulfill the
revised classification criteria for APS.
3.1. IgA aCL and IgA anti-β2GPI antibodies
Although standard serological tests included in the current laboratory classification criteria
for APS [11] detect IgG and IgM isotypes for the aCL and anti-β2GPI but not the IgA isotype,
clinicians will occasionally encounter patients with isolated IgA aPL who exhibit clinical
manifestations of APS. Most studies to date have mainly focused on the IgG/IgM isotypes of
aPL, with only rare reports pointing to the possible clinical significance of IgA aPL. The
literature on IgA aPL is quite heterogeneous, reporting a high variability in their prevalence
and clinical significance due to different study designs and populations studied and different
laboratory methods (in-house as well as commercial kits) with different cutoffs and different
ethnic populations (review in [98]). IgA aCL and anti-β2GPI antibodies have been reported in
up to 70% of patients with systemic lupus erythematosus (SLE) and in those with primary APS
[98]. The role of IgA isotypes of both antibodies in APS is however unclear. Lagos et al. [99]
found that livedo reticularis, heart valve disease, thrombocytopenia, and epilepsy are more
common among subjects with increased IgA anti-β2GPI antibodies [99]. A similar association
was observed in SLE patients [100].
The reports on the prevalence of IgA aCL are extremely variable ranging from 0% to nearly
50% [28]. Altogether, twelve studies showed an association between IgA aCL and certain
clinical features related to APS but fifteen studies failed to find any relationship between the
presence of IgA aCL and the clinical signs of APS (review in [28]). Studies investigating
diagnostic applicability and added value of IgA aCL determination show a general weakness,
seeing as elevated value of IgA aCL are often accompanied with positive IgG and/or IgM aCL,
making it difficult to understand the role of elevated IgA aCL alone. In addition, a great
variability of results suggests that studies are barely comparable in the population included,
regarding methods used and results obtained. Some differences among studies can also be due
to different ethnicity. IgA seems to be the most prevalent isotype of aCL in African Americans
[101], African Caribbean [102], and Japanese patients [103].
There is also a controversy in the literature regarding the meaning of elevated IgA anti-β2GPI.
The majority of published papers have highlighted the value of IgA anti-β2GPI in the diagnosis
of APS [28]. Thrombosis, particularly arterial thrombosis [86, 104, 105], is frequently found
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associated with IgA anti-β2GPI, although the simultaneous presence of other isotypes makes
it often difficult to interpret. Mehrani et al. [106] reported on a high prevalence of IgA aPL
antibodies with 20% positive IgA anti-β2GPI associated with deep vein thrombosis. IgA anti-
β2GPI seems to be more prevalent in SLE patients compared to IgA aCL (review in [98]).
Therefore, IgA anti-β2GPI have gained clinical relevance and were recently included among
aPL tests in the novel SLICC classification criteria for SLE [107]. Ruiz-García et al. [108] also
suggested that the assessment of IgA anti-β2GPI in patients with suspected primary APS is
important for the identification, treatment, and management of patients who in accordance
with the current classification criteria are not diagnosed at this point of the disease since the
serological profile of patients with primary APS (where IgA is the most prevalent isotype) is
different from systemic autoimmune disorders-associated APS (where IgG is the most
prevalent isotype). Therefore, in selected patients where the clinical suspicion of APS is high
but all tests for other antiphospholipid antibodies are negative, testing for IgA anti-β2GPI
might be clinically useful and therefore recommended [58, 93, 109]. Despierres et al. [105] also
proposed that IgA anti-β2GPI should be searched for in all patients with unexplained throm‐
bosis based on their finding that IgA anti-β2GPI was associated with thrombosis even in non-
SLE patients. Most patients positive for IgA anti-β2GPI were negative for IgA aCL [108, 109].
In addition, a subpopulation of IgA anti-β2GPI directed against domain IV has been linked to
atherosclerosis in a study using different β2GPI domain-deleted mutants and native β2GPI [86].
Akhter et al. also reported that in a large cohort of nearly 300 SLE patients, the only assay with
a significant association with stroke was the IgA anti-β2GPI directed against domain IV/V [104].
3.2. Anti-domain I β2GPI antibodies
For better clinical diagnosis and management of APS, a lot of efforts have been implicated for
better characterization of pathogenic function and clinical significance of anti-β2GPI. Several
groups have studied the fine specificity of anti-β2GPI, and every domain of β2GPI has been
described to bind antibodies [63]. From an immunologic point of view, it is hard to imagine a
self-protein containing many immunodominant epitopes. Therefore, many studies have been
initiated to identify the most immunodominant epitope. Most evidence points to the domain
I (DI) of β2GPI. A specific epitope in DI is a positively charged discontinuous structure located
in the N-terminal of β2GPI and has been identified as the most relevant antigenic target
involved in the binding of anti-β2GPI to β2GPI [110]. The reactivity to DI was first described
by Iverson et al. in 1998, who showed that most anti-β2GPI reacted with DI of β2GPI using
domain-deletion mutants of the protein [111]. The binding of anti-DI anti-β2GPI (anti-β2GPI-
DI) to β2GPI is conformation dependent [110]. In the circular conformation of β2GPI, DI
interacts with domain V, and immunodominant epitope is therefore hidden. When β2GPI takes
the intermediate S-shape, the epitope in the DI is covered by carbohydrate chains of domain
III and domain IV, thus preventing the binding of antibodies to β2GPI [74]. The binding of β2GPI
to the anionic surface may induce conformational change of β2GPI from circular to J-shaped
conformation, which also results in the displacement of the domains III–IV carbohydrate side
chains; the critical epitope arginine 39-glycine 43 is exposed and thus becomes accessible for
domain-specific anti-β2GPI binding [74]. Despite a wide interest in the potential diagnostic
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value of these DI-specific antibodies in the diagnosis of APS, specifically anti-β2GPI-DI, the
number of studies is still limited, and their potential clinical utility has not been widely
accepted [112]. Anti-β2GPI-DI antibodies have attracted particular interest as they are strongly
associated with thrombosis [77, 113–115]. Ciesla et al. [116] found that increased IgG anti-β2GPI-
DI antibodies were associated with livedo reticularis and heart valve disease in APS, which is
also in concordance with the finding of de Laat and coworkers [63]. The later have also reported
of IgG anti-β2GPI-DI antibodies to be associated with heart valve disease presumably linked
to thrombotic processes on a valve with autoimmune valvulitis, being a risk factor for stroke.
To date, there have been no commercial kits to detect anti-β2GPI-DI antibodies available on
the market; however, several research methods have been developed [110]. As the binding of
anti-β2GPI-DI antibodies might be directly affected with conformational changes of β2GPI, the
preparation and coating β2GPI to ELISA trays is of major importance for the results of the
assay. It has been consistently observed that anti-β2GPI-DI antibodies react with their target
epitope only when DI is bound onto hydrophobic but not hydrophilic surface. The majority
of studies used the two steps ELISA using β2GPI-DI coated on hydrophobic and hydrophilic
microtitre plates [110, 113, 117]. This method is based on the assumption that the epitope of
β2GPI-DI is exposed only to the hydrophilic surface of the microtitre plates and thus accessible
for autoantibody binding [113]. Pozzi et al. showed that the capture ELISA with chemical
synthesized N-terminally biotinylated β2GPI-DI on streptavidin plates was able to discrimi‐
nate between APS patients and controls in contrast to nonbiotinylated β2GPI-DI directly
immobilized onto ELISA plates [118]. A liquid phase inhibition assay using a whole β2GPI
immobilized on the solid phase and synthetic β2GPI-DI as inhibitor was also developed [119].
In addition, Iverson and coworkers developed an ELISA, which was based on recombinant
β2GPI-DI expressed and purified from insect cells [120]. Recently, a novel β2GPI-DI chemilu‐
minescence immunoassay (CIA, INOVA Diagnostics, San Diego, USA) based on the BIO-
FLASH system (Biokit, Barcelona, Spain) and using a recombinant β2GPI-DI coupled to
paramagnetic beads has been developed [121]. Despite comparability between solid phase
assays and a CIA immunoassay, results obtained by both approaches should be evaluated in
a larger multicentre studies in order to confirm the reproducibility of different anti-β2GPI-DI
antibody assays. It is also premature to replace the anti-β2GPI ELISA with the anti-β2GPI-DI
assays, as there is still the possibility that other populations of thrombosis related antibodies
are present.
3.3. Antiprothrombin antibodies
Prothrombin, a phospholipid binding protein, was first proposed as a possible co-factor for
LA by Loeliger in 1959 [122]. In 1983, Bajaj and his colleagues were the first to ascertain the
evidence of prothrombin binding antibodies in two patients with LA and severe hypopro‐
thrombinemia [123]. These antibodies bound prothrombin without preventing its activation
to thrombin. The authors assumed that the hypoprothrombinemia resulted in a rapid removal
of prothrombin–antibody complexes from circulation. A year later, the existence of prothrom‐
bin–antiprothrombin immune complex was confirmed with counterimmunoelectrophoresis
(CIE) in the plasma of patients with LA, but without hypoprothrombinemia [124]. Fleck et al.
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confirmed these findings, showing that 74% of patients with LA had evidence of anti-pro‐
thrombin antibodies on CIE and that antiprothrombin antibodies exhibit LA activity [125].
Bevers et al. highlighted the role of antiprothrombin antibodies for the LA activity in patients
with elevated aCL and LA [126]. In eleven out of sixteen patients’ sera, the binding to phos‐
pholipid surface was detected only in the presence of prothrombin and calcium ions. Later,
Oosting and his colleagues demonstrated that antibodies with LA activity inhibited prothrom‐
binase complexes on the surface of endothelial cells and that IgG fraction with LA activity
bound the phospholipid-prothrombin immune complexes [127]. A review elucidated that
majority of antibodies with LA activity bind prothrombin and/or β2GPI [128]. Double diffusion
and CIE were the first techniques used for the detection of antiprothrombin antibodies [123–
125, 129]. Their main advantage was in the measurement of prothrombin–antiprothrombin
immune complexes. These in vitro findings have indicated that such complexes might exist in
plasma, but detection methods used did not enable quantitative measurements. In many cases,
the titer and/or affinity of antiprothrombin antibodies were too low to obtain a clear precipi‐
tation line. Other techniques based their detection on the impairment of enzyme activity of
prothrombin after binding with relevant antibodies [127, 130]. The need for isolation of
antiprothrombin antibodies and purification of clotting factors makes these methods unsuit‐
able for routine work.
In the last few years, several research groups developed various ELISAs, which are by far most
widely used techniques for the determination of antiprothrombin antibodies, since they enable
relatively quick determination of a titre and antibody isotype. Arvieux et al. first presented an
ELISA, where prothrombin as the antigen was applied to high binding microtitre plates [131].
In this way, they determined antibodies directed against prothrombin alone (aPT-A or aPT). It
is important to note that the manner of prothrombin presentation on a solid surface greatly
affects its recognition by antiprothrombin antibodies [132]. Antiprothrombin antibodies only
bind prothrombin when immobilized on an appropriate anionic surface such as γ-irradiated or
high binding polyvinylchloride (PVC) microtitre plates, or to prothrombin exposed to the
immobilized anionic phospholipids. Antiprothrombin antibodies cannot be detected when
prothrombin is immobilized on nonirradiated plates [131]. In this respect, the reactivity of
antiprothrombin antibodies in an ELISA strongly resembles the reactivity of low-avidity anti-
β2GPI. The latter recognizes β2GPI only when bound to the anionic surface, while their binding
to the antigen in liquid phase is minimal [133–135]. Matsuuda et al. [136] showed that antipro‐
thrombin antibodies could be detected also by an ELISA where prothrombin is bound to
immobilized phosphatidylserine (aPS/PT ELISA). Soon it was shown that aPS/PT ELISA was
more efficient in determination of antiprothrombin antibodies in comparison to aPT ELISA
[137]. The phenomenon can be explained in several ways: (1) prothrombin, bound to phospha‐
tidylserine, is not limited in its lateral movement, in contrast with prothrombin bound to high-
binding microtitre plates resulting in clustering and proper orientation of prothrombin offering
better conditions for antibody binding; (2) ELISA with phosphatidylserine in solid phase may,
through the calcium ions,  capture the circulating prothrombin–antiprothrombin immune
complexes present in certain samples; and (3) antiprothrombin antibodies may react with
neoepitopes occurring on prothrombin molecules only when bound to phosphatidylserine
through calcium ions. Altogether, aPS/PT ELISA better simulates the in vivo conditions, where
prothrombin and antiprothrombin antibodies presumably bind to phospholipid surface of
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endothelial cells. In addition, Atsumi et al. showed that the aPS/PT strongly correlated with LA
activity [138]. This group showed there was no correlation between the levels of aPS/PT and
aPT in patients with APS and therefore assumed that the aPS/PT ELISA determines, at least in
part, different antibodies compared to aPT ELISA. The first published aPS/PT protocol was later
modified in order to increase the analytical sensitivity of the test [139]. The modified proce‐
dure allowed the detection of the two allegedly different populations of antibodies and thus
determination of all clinically relevant antiprothrombin antibodies with one method. The
authors reported that their in-house aPS/PT ELISA was the most optimal method for the
determination of all clinically relevant aPS/PT antibodies, exhibiting the highest percentage of
LA activity,  compared to aCL and anti-β2GPI [139].  The ELISA protocol is schematically
presented in Figure 3. Briefly, medium binding plates were coated with phosphatidylserine in
chloroform/methanol 1:4 and dried overnight at 4°C. Following blocking with Tris-buffered
saline (TBS) containing 1% bovine serum albumin (BSA) and 5 mM CaCl2 (1% BSA/TBS-Ca) and
two washes with 5 mM CaCl2-TBS–0.05% Tween 20 (TBS-Tw), human prothrombin of final
concentration 10 mg/L and patients’ sera diluted 1:100 were applied to wells immediately one
after the other and incubated for 1 h at room temperature. After 4 washes, alkaline-conjugat‐
ed goat anti-human IgG or IgM were applied in 1% BSA/TBS-Ca and incubated for 30 min.
Following 4 washes in TBS/Tw, 100 µl/well of para-nitrophenylphosphate in diethanolamine
buffer (pH 9.8) was applied and OD405 was kinetically measured by a spectrometer (Figure 3).
Zigon et al. also showed that antiprothrombin antibodies are of different avidity, which greatly
impacts their detection by different ELISAs [139, 140]. It was shown that low-avidity antipro‐
thrombin antibodies were detectable only in the aPS/PT ELISA, while aPT ELISA detected only
antibodies with predominantly heterogeneous avidity. Initially, only a few commercial kits for
the  detection  of  antiprothrombin  antibodies  were  available,  and they  all  measured  aPT
antibodies. Their overall diagnostic sensitivity and specificity was poor [141]. In 2010, the
commercial QUANTA LiteTM aPS/PT IgG/IgM and LAC assays became available as an aid to
the diagnosis of APS [15, 142]. Zigon et al. showed that results measured with QUANTA LiteTM
aPS/PT  highly  correlated  with  their  modified  in-house  procedure  described  above  and
confirmed that both ELISAs have high diagnostic specificity and sensitivity for APS [15].
Several retrospective and cross-sectional studies, which were first summarized in Galli et al.
[143] and recently in Sciasca et al. [14], had examined the clinical significance of antibodies to
prothrombin determined by ELISA. Different laboratories performed their variation of ELISA
methods  using  commercially  available  assay  kits  for  the  determination  of  antibodies  to
prothrombin. International studies that have attempted to standardize and unify these methods
were very rare [141]. The main reasons for significant differences in results among published
studies  are  modified procedures,  different  reagents  used,  and the fact  that  international
standards are not available. Comparative studies of two methods aPT or aPS/PT ELISA showed
that the results only partially overlap, which means that some patients were positive in only
one ELISA [141, 144–146]. Researchers then speculated that results from aPT ELISA and from
aPS/PT ELISA allegedly do not belong to the same population of antibodies, although both are
clinically associated with APS. Many have therefore estimated that in terms of clinical signifi‐
cance, it is necessary to consider the results of the two performances. A recent systematic review
of studies on aPT (38 studies) and aPS/PT (10 studies) summarizes the results of more than 7000
patients and controls. Both types of antiprothrombin antibodies represent an increased risk for
thrombosis, but meta-analysis in the article showed that elevated aPS/PT pose a greater risk for
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arterial and/or venous thrombosis compared with aPT (OR = 5.1, 95% CI = 4.2 to 6.3 and OR =
1.8, 95% CI = 1.4 to 2.8). The authors concluded that routine measurements of aPS/PT, but not
aPT, allow better insight to thrombotic risk in patients with systemic autoimmune diseases as
well as confirm an undeniable need for further research toward the inclusion of these antibod‐
ies in laboratory criteria for APS.
Results of a modified aPS/PT ELISA [15] have shown that elevated aPS/PT represent an
increased risk of venous thrombosis (OR = 3.5, 95% CI = 1.7 to 7.0) and less so for arterial
thrombosis (OR = 1.9, 95% CI = 0.9 to 4.1) (Table 1). A very important finding was that
antibodies to prothrombin compared to other aPL (LA, aCL, and anti-β2GPI) represented the
highest risk for pregnancy complications (OR = 9.3, 95% CI = 3.5 to 24.6). Not many studies
have investigated the relationship between antibodies to prothrombin and complications
during pregnancy, and about half of these studies have not confirmed such correlations [145,
147–150]. In contrast, Akimoto [151] and Bertolaccini [152] and their colleagues showed strong
and specific association between different types of antibodies to prothrombin and miscarriag‐
es. Clinical correlations between antibodies and late pregnancy complications were later
confirmed by two other studies [153, 154], but none of the studies found any link between
complications in early pregnancy before 12 weeks of pregnancy and the presence of antibodies
to prothrombin. The most recent study clearly showed an overall prevalence of aPS/PT of
13.0%, aCL of 12.4%, LA, and anti-β2GPI less than 8.0% in a group of patients with obstetric
complications characteristic for APS. Both aPS/PT and aCL were significantly more prevalent
compared to healthy blood donors. However, aCL correlated only with late pregnancy
morbidity and prematurity, while aPS/PT were the only antibodies associated with early
recurrent pregnancy loss, as well as with late pregnancy morbidity and prematurity. Authors
suggested that, aPS/PT measurement might improve the evaluation of patients with early
recurrent pregnancy loss, undiscovered by other aPL tests [155].
 
Antibody p-value 
Odds ratio 
(95% CI)
Sensitivity % Specificity % p-value 
Odds ratio 
(95% CI)
Sensitivity % Specificity % p-value 
Odds ratio 
(95% CI)
Sensitivity % Specificity %
LA 0.43 1.4 (0.6-2.9) 49 59 <0.001 5.6 (2.6-12.2) 70 70 <0.005 4.3 (1.6-11.9) 62 73
IgG <0.001 5.5 (2.3-13.4) 83 53 <0.005 3.0 (1.5-6.2) 74 52 <0.001 5.8 (2.1-15.9) 79 61
 IgM 0.67 1.2 (0.4-3.5) 15 88 0.010 3.5 (1.3-9.2) 23 92 0.130 2.5 (0.8-7.8) 21 90
IgG 0.02 2.4 (1.2-5.1) 63 58 <0.001 3.2 (1.6-6.5) 66 63 0.002 4.1 (1.7-10.4) 68 66
 IgM 0.99 1.0 (0.3-2.9) 12 88 0.070 2.5 (0.9-6.5) 19 91 0.278 2.0 (0.6-6.6) 18 90
IgG 0.08 1.9 (0.9-4.1 44 71 <0.001 3.5 (1.7-7.0) 51 77 <0.001 9.3 (3.5-24.6) 64 84
 IgM 0.36 1.4 (0.6-2.9) 39 69 0.021 2.2 (1.1-4.5) 45 73 <0.005 4.0 (1.6-9.9) 54 78
Obstetric complications (n=28)Venous thrombosis (n=53)
aCL
anti-β2GPI
aPS/PT 
Arterial thrombosis (n=41)
Table 1. Antiphospholipid antibodies and LA in relationship to arterial thrombosis (AT), venous thrombosis (VT), and
obstetric complications (OC). aCL: anticardiolipin; anti-β2GPI: anti-β2glycoprotein; aPS/PT anti-phosphatidylserine/
prothrombin; LA: lupus anticoagulant; OR: odds ratio; CI: confidence interval.
4. Novel/future methodology
Given the poor standardization of single aPL testing, new technical approaches to aPL profiling
have been proposed recently, which elucidated the possibility of aPL profiling for the diagnosis
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of APS and outcome prediction [22, 24, 156]. In order to ensure the quality of routine laboratory
measurements, along with time and cost-efficiency, multiline immunodot assays or bead-
based multiplex techniques might represent a solution for these challenges. Apart from the
immunodot technique, the detection of aPL by flow cytometry using beads with particular
surface properties seems to represent another promising approach in aPL antibody multiplex
testing [23]. In the future, we can also expect studies exploring miRNAs as biomarkers for risk
of thrombosis and/or obstetric complication. Many miRNAs have been found significantly
altered in sera or plasma of patients with thrombosis [25] or specific pregnancy complications
[26, 27].
4.1. Multiplex assays
Recently, the parallel detection of aCL and anti-β2GPI antibodies of IgG, IgA, and IgM isotypes
related to APS was developed in the BioPlex system (BioPlex™ 2200 multiplex immunoassay
system using APLS reagents). A unique fully automated multiplex immunoassay platform
that allows the qualitative and quantitative measurements of several antibodies was developed
[24]. The instrument combines the multianalyte profiling technology with antigen-coated
fluoromagnetic beads as the solid phase, in an automated platform where sampling, process‐
ing, and data reduction are performed automatically. Unlike other methods, beads are washed
after incubation and labeling; magnetic beads are used to automate washing steps and support
random access testing [157]. The BioPlex APLS system seems to have a good diagnostic
accuracy for all tests. However, the simultaneous detection of aCL and anti-β2GPI of IgA
isotype together with IgG and IgM isotypes did not increase the diagnostic sensitivity for APS.
This was the first and until now the only study on the BioPlex APLS system; therefore, the
applicability of this technology needs to be further explored and confirmed.
4.2. Multiline immunodot assays
A multiline immunodot assay (MLDA) uses a different solid phase and is an alternative to
ELISA for simultaneous assessment of multiple aPL. Only one research group reported the
use of hydrophobic membrane as the solid phase for immobilization of phospholipids in aPL
antibody testing [22, 156, 158, 159]. The anionic phospholipids CL, phosphatidylinositol, and
phosphatidylserine were immobilized in lines together with the co-factor protein β2GPI and a
reaction control reactant on a polyvinylidene difluoride (PVDF) membrane strip to detect
specific autoantibodies simultaneously in one sample. Membrane surfaces like the hydropho‐
bic PVDF membrane seemed to induce surprisingly the same conformational changes in the
β2GPI polypeptide required for disease-specific aPL. It may be assumed that the membrane
immobilization mimics the in vivo presentation of anionic phospholipids in membranes more
appropriately since the majority of aPL antibodies are supposed to be of medium or rather low
affinity and bivalent binding is required for strong amplification of interaction. The formation
of multiple interconnected immune complexes on an appropriate lipid surface might be of
importance for antibody testing. Authors of the study explained that MLDA provided the
appropriate reaction environment for the detection of three different aPL antibody reactivities.
First, aPL antibodies to pure anionic phospholipids were determined; second, immobilized
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phospholipids interacting with cofactor-aPL antibody complexes were detected; and third,
antibodies against cofactor proteins alone could be detected. Therefore, this technique may
assess a broader spectrum of reactivity in a multiplex format for aPL antibody profiling than
the recommended ELISA technique does. However, the inability of quantification and the lack
of confirmation by other researchers make this very novel methodology questionable.
4.3. miRNAs
MicroRNAs (miRNAs) are small noncoding RNAs with 21 to 25 nucleotides in length that
posttranslationally regulate gene expression. miRNAs are fundamentally involved in the
regulation of major biological processes in health and disease. The primary miRNA sequence
repository—miRBase database (http://www.mirbase.org/), the latest miRBase release (v20,
June 2013), contains 24521 miRNA loci from 206 species, processed to produce 30424 mature
miRNA products [160].
Since the discovery that miRNAs are highly stable in circulation [161, 162], circulating serum/
plasma miRNAs have gained an extensive research interest as highly promising noninvasive
clinical biomarkers in diagnosis, prognosis, treatment response, and risk assessment in several
diseases, including cancer [163, 164] autoimmune diseases [165, 166], myocardial infarction
[167], heart failure [168], deep vein thrombosis [169], and pregnancy complications (reviewed
in [170, 171]).
Williams et al. showed that the vast majority of circulating miRNAs in healthy human plasma
originated from blood components and endothelial cells, and tissue-specific miRNAs from gut
and liver were represented as well [172]. This suggested broad tissue contribution to the
circulating pool of miRNAs in healthy human plasma. In contrast, skeletal muscle-, heart-, and
brain-specific miRNAs were detected only at very low levels in healthy plasma, suggesting
that such miRNAs, when detected in circulation at increased levels may specifically reflect
source tissue damage or disease. The strong evidence for the existence of the circulating organ-
specific miRNAs in tissue damage or disease comes, for example, from the study of circulating
miRNAs in myocardial injury in patients with advanced heart failure [168]. In this study,
cardiac-specific (miR-208b, miR-208a, and miR-449) and muscle-specific (miR-1-1 and
miR-133b) circulating miRNAs (myomirs) increased up to 140-fold in patients with advanced
heart failure as compared to subject without heart disease and highly correlated to the levels
of cardiac troponin I, the established marker of heart injury.
The potential for shedding the tissue-specific miRNAs in the circulation during organ damage
or disease, alongside their high stability in serum and plasma, equips circulating tissue-specific
miRNAs with high potential for clinical biomarker applications. However, to reach significant
levels in the circulation, tissue-specific miRNA biomarker has to be abundantly present in the
damaged source tissue as, for example, in advanced heart failure [168]. In addition, the source
tissue has to be well perfused and of considerable size to be able to contribute to the circulating
miRNA pool. According to the experimental estimations of circulating placental miRNAs [172]
and mathematical modeling [173], the tumors should reach a considerable size (0.3–0.6 g)
before tumor miRNAs could reach the detection threshold in plasma. A lack of cancer-specific
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miRNAs, small tumor biomass early in disease, and the dilution of tissue-specific miRNAs in
circulation may hinder the early detection of tumor-derived circulating miRNAs. Given the
promise of miRNAs as noninvasive clinical biomarkers, different strategies have been
suggested to overcome these limitations early in disease, when the detection of tumors is most
desirable [174]. Circulating miRNAs are primarily associated with Argonaute complexes, and
a minor part of circulating miRNA is contained within extracellular vesicles (EVs) [175]. EVs
are shed in a highly regulated manner from their cells of origin and are reported to have disease
unique signatures of nucleic acids [176]. Therefore, the selective detection of EV-associated
circulating miRNAs could prove valuable in enriching the low abundant tissue-specific
circulating miRNAs [174].
Despite the exponential increase in the number of studies on circulating miRNAs as disease
biomarkers over the last years, circulating miRNAs are in the infancy toward becoming highly
specific clinical biomarkers. Many circulating miRNAs, identified as potential disease bio‐
markers, are associated with a variety of diseases. Furthermore, reported miRNA profiles for
a given disease significantly differ between different studies. This can be in part attributed to
the current methodological limitations for detecting low level circulating miRNAs, as well as
to the preanalytical and the heterogeneity of studied cohorts.
Preanalytical variables during collection and processing of blood to obtain cell-free, circulating
miRNAs may significantly affect the levels of circulating miRNAs as excellently reviewed by
Nair et al. [177]. Therefore, all the study samples should be obtained in the same way, using
standard operating procedure for sample collection and processing to minimize the preana‐
lytical variability in circulating miRNA detection. An important source of the preanalytical
variability, that considerably affect circulating miRNA levels, is the contamination of circu‐
lating cell-free miRNAs with cellular miRNAs, originating from epithelial cells at the site of
skin puncture, red blood cell hemolysis releasing a large amount of contaminating miRNAs,
as well as from contaminating monocytes and/or platelets. Such cellular contamination could
be minimized by discarding first milliliters of withdrawn blood, using a larger-gauge needle,
minimizing tourniquet use, using adequate centrifugation speed and preparing platelet-free
plasma (reviewed in [177]). Several miRNAs have been identified, which can estimate the
contribution of different cellular contaminants, such as platelets or red blood cell lysis, to the
plasma miRNA profile [178, 179]. In addition, study subjects have to be matched for age, sex,
smoking history, and end-stage organ dysfunction, or miRNA levels have to be adjusted for
these confounders, known to significantly affect miRNA levels (reviewed in [177]).
To measure circulating miRNA levels, several methods could be used, including quantitative
PCR, high-density microarray technology or next generation sequencing. When using plasma
as a source biofluid for circulating miRNA detection heparin should be avoided as it may
inhibit qPCR. Another critical step in the analysis of circulating miRNA is data normalization,
which is rather challenging when compared to the analysis of cellular and tissue miRNA
expression. Normalization strategies significantly vary across the published studies on
circulating miRNAs, further contributing to analytical variability. In contrast to the measure‐
ment of cellular miRNAs, there is no optimal housekeeping gene for normalization of circu‐
lating RNA levels, and a global median normalization can be used as a normalization method.
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The simplest method to normalize circulating miRNA levels is to use the defined plasma
volume, from which RNA is isolated, combined with the “Spike In” exogenous miRNA
controls. The use of “Spike In” exogenous miRNA controls, derived, e.g., from Caenorhabditis
elegans (cel-miR-39), is highly recommended during the isolation of RNA from plasma or
serum as quality control for the technical variation arising from variations in RNA isolation,
and the differential efficiencies of the reverse transcription and real-time PCR [179, 180].
Up to date, no reports exist on investigating the circulating levels of miRNAs in APS patients.
Nevertheless, the down-regulation of tissue factor-targeting miRNAs, miR-19b, and miR-20a
in peripheral blood monocytes from SLE and APS patients as compared to healthy controls
inversely correlated with the surface tissue factor expression on monocytes and may contribute
to the increased thrombosis risk in APS and SLE patients [181]. Circulating miRNAs may prove
valuable as biomarkers in APS, in particular in patients with obstetric APS and APS-related
placental dysfunction. Human placenta is a relatively large, well-perfused organ, present only
during pregnancy, which makes it an excellent solid tissue model, very likely to contribute to
the pool of circulating miRNAs. During pregnancy, placenta-specific miRNAs are detected in
maternal circulation. Many of these miRNAs exhibit strict placental specificity and cannot be
detected in paternal circulation or plasma of nonpregnant control women [172]. Specifically,
the characterization of circulating and placental miRNAs by small RNA deep sequencing
showed strong 5240-fold and 28-fold enrichment of the miR-498 cluster in placentas and
maternal plasma, respectively, as compared to paternal plasma. This indicated strong, tissue-
specific contribution of placenta to the maternal circulating miRNA pool. Furthermore,
placental miRNA fingerprints, including miR-498 cluster isomiRs, were sufficiently unique
between the subjects to enable matching of the maternal plasma sample to its specific source
placenta. This suggests that clinically relevant alterations of placental miRNAs may be present
in maternal plasma of women with pregnancy complications, such as preeclampsia or obstetric
APS. Such miRNAs could serve as noninvasive biomarkers of placental disease in obstetric
APS, allowing for its better monitoring and on time intervention.
5. Conclusion
The classification of APS is based on three aPL laboratory tests that need to be positive in
addition to its clinical manifestations. Both the clinical spectrum of APS and the serological
markers are more polymorphic than it was thought in the past. Additional laboratory tests
have been proposed in order to improve the diagnostic and predictive power, but promising
results have been reported especially for anti-β2GPI-DI and anti-PS/PT antibodies. Discovering
new markers did not ease the recognition of patients with APS, and therefore modern trends
propose the determination of multiple classes of aPL to gain a common score, which could
estimate the risk for arterial/venous thrombosis in APS patients. Risk stratification itself
represents a major challenge. However, the potential roles of aPL (as a risk or even as a
prognostic factor for arterial/venous thrombosis and miscarriages) will occupy future debates.
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